The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.

A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.

During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.

AI is revolutionizing the pharma supply chain by automating manual tasks, monitoring risks and providing predictive insights.

CirCode Biomed’s circular RNA drug HM2002 has received IND clearance from the FDA for the treatment of ischaemic heart ...

Juvenescence has acquired Ro5 to enhance its AI/machine learning capabilities and improve research and development.

China’s NMPA has approved Akeso's PD-1/CTLA-4 bispecific antibody, cadonilimab, to treat persistent, recurrent or metastatic ...

The alert comes amid some patients accessing GLP-1RAs through unregulated channels, where safety information is often not ...

The European Commission (EC) has granted approval for Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin).

Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

In this issue: assessing the regulators' role as AI in clinical trials evolves, the potential for a newborn screening refresh ...